Drug intelligence / Profile preview

phentermine (CTS)

Development stage
Approved
Lead developer
CTS
Modality
Small Molecules
Administration
Oral
01

Overview

Razin is a brand name for **phentermine**, a sympathomimetic amine anorectic used as a short-term adjunct in the management of exogenous obesity. Developed and marketed by the Israeli pharmaceutical company **CTS**, Razin is indicated for patients with an initial body mass index (BMI) of 30 kg/m² or greater, or 27 kg/m² or greater in the presence of other risk factors (e.g., controlled hypertension, diabetes, hyperlipidemia). The drug functions as an appetite suppressant by stimulating the release of norepinephrine in the hypothalamus, which reduces the sensation of hunger. It is chemically related to amphetamine but is primarily used for its weight-loss properties rather than central nervous system stimulation. Razin is typically administered orally in capsule form as part of a comprehensive weight reduction program that includes exercise and caloric restriction.

Brand names
RazinAdipex-PLomairaDuromineSuprenza
Other names
phentermine hydrochloridephenyl-tertiary-butylamine
02

Targets

DAT (Dopamine plasma membrane transport protein)TAAR1 (Trace amine-associated receptor 1)SERT (Sodium-dependent serotonin transporter)NET (Norepinephrine Transporter)VMAT2 (Vesicular monoamine transporter 2)

Beyond the preview

Go deeper on phentermine (CTS).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on phentermine (CTS).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call